{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:19:50Z","timestamp":1761895190383},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,11,4]],"date-time":"2010-11-04T00:00:00Z","timestamp":1288828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/ar3149","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T15:16:44Z","timestamp":1288970204000},"source":"Crossref","is-referenced-by-count":14,"title":["Applying science in practice: the optimization of biological therapy in rheumatoid arthritis"],"prefix":"10.1186","volume":"12","author":[{"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Jasvinder A","family":"Singh","sequence":"additional","affiliation":[]},{"given":"Robert B","family":"Landew\u00e9","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Ant\u00f3nio P","family":"da Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,11,4]]},"reference":[{"key":"9752_CR1","first-page":"1","volume":"32","author":"M Dougados","year":"2005","unstructured":"Dougados M: It's good to feel better but it's better to feel good. J Rheumatol. 2005, 32: 1-2.","journal-title":"J Rheumatol"},{"key":"9752_CR2","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.23733","volume":"58","author":"D Aletaha","year":"2008","unstructured":"Aletaha D, Funovits J, Smolen JS: The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum. 2008, 58: 2622-2631. 10.1002\/art.23733.","journal-title":"Arthritis Rheum"},{"key":"9752_CR3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","volume":"68","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009, 68: 823-827. 10.1136\/ard.2008.090019.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.20716","volume":"52","author":"K Puolakka","year":"2005","unstructured":"Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, Jarvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005, 52: 36-41. 10.1002\/art.20716.","journal-title":"Arthritis Rheum"},{"key":"9752_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7","volume":"43","author":"D Krause","year":"2000","unstructured":"Krause D, Schleusser B, Herborn G, Rau R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000, 43: 14-21. 10.1002\/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7.","journal-title":"Arthritis Rheum"},{"key":"9752_CR6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002, 359: 1173-1177. 10.1016\/S0140-6736(02)08213-2.","journal-title":"Lancet"},{"key":"9752_CR7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/ard.2006.062497","volume":"66","author":"LT Jacobsson","year":"2007","unstructured":"Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 670-675. 10.1136\/ard.2006.062497.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.24367","volume":"61","author":"SM van der Kooij","year":"2009","unstructured":"van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, Allaart CF: Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum. 2009, 61: 4-12.","journal-title":"Arthritis Rheum"},{"key":"9752_CR9","volume-title":"Paper presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology; 17-21","author":"H Radner","year":"2009","unstructured":"Radner H, Smolen J, Aletaha D: Remission of rheumatoid arthritis: benefits from socioeconomic and quality of life perspectives. Paper presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology; 17-21. 2009, Abstract 1382, October ; Philadelphia, PA"},{"key":"9752_CR10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez- Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010, 69: 631-637. 10.1136\/ard.2009.123919.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"9752_CR11","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1136\/ard.59.suppl_1.i28","volume":"59","author":"PL van Riel","year":"2000","unstructured":"van Riel PL, van Gestel AM: Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000, 59 (Suppl 1): i28-31. 10.1136\/ard.59.suppl_1.i28.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR12","first-page":"S","volume":"24","author":"VK Ranganath","year":"2006","unstructured":"Ranganath VK, Khanna D, Paulus HE: ACR remission criteria and response criteria. Clin Exp Rheumatol. 2006, 24: S-14-21.","journal-title":"Clin Exp Rheumatol"},{"key":"9752_CR13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.clinthera.2009.06.005","volume":"31","author":"MJ Bergman","year":"2009","unstructured":"Bergman MJ: Assessing adequate treatment response in patients with rheumatoid arthritis. Clin Ther. 2009, 31: 1219-1231. 10.1016\/j.clinthera.2009.06.005.","journal-title":"Clin Ther"},{"key":"9752_CR14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/art.24392","volume":"61","author":"LH van Tuyl","year":"2009","unstructured":"van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M: Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology\/European League Against Rheumatism consensus conference. Arthritis Rheum. 2009, 61: 704-710. 10.1002\/art.24392.","journal-title":"Arthritis Rheum"},{"key":"9752_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.semarthrit.2005.06.003","volume":"35","author":"CA Sesin","year":"2005","unstructured":"Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality?. Semin Arthritis Rheum. 2005, 35: 185-196. 10.1016\/j.semarthrit.2005.06.003.","journal-title":"Semin Arthritis Rheum"},{"key":"9752_CR16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","volume":"46","author":"M Mierau","year":"2007","unstructured":"Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS: Assessing remission in clinical practice. Rheumatology (Oxford). 2007, 46: 975-979. 10.1093\/rheumatology\/kem007.","journal-title":"Rheumatology (Oxford)"},{"key":"9752_CR17","first-page":"S","volume":"24","author":"H Makinen","year":"2006","unstructured":"Makinen H, Hannonen P, Sokka T: Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol. 2006, 24: S-22-28.","journal-title":"Clin Exp Rheumatol"},{"key":"9752_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","volume":"50","author":"ET Molenaar","year":"2004","unstructured":"Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004, 50: 36-42. 10.1002\/art.11481.","journal-title":"Arthritis Rheum"},{"key":"9752_CR19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","volume":"24","author":"RS Pinals","year":"1981","unstructured":"Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981, 24: 1308-1315. 10.1002\/art.1780241012.","journal-title":"Arthritis Rheum"},{"key":"9752_CR20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","volume":"35","author":"ML Prevoo","year":"1996","unstructured":"Prevoo ML, van Gestel AM, van THMA, van Rijswijk MH, van de Putte LB, van Riel PL: Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996, 35: 1101-1105. 10.1093\/rheumatology\/35.11.1101.","journal-title":"Br J Rheumatol"},{"key":"9752_CR21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","volume":"43","author":"J Fransen","year":"2004","unstructured":"Fransen J, Creemers MC, Van Riel PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004, 43: 1252-1255. 10.1093\/rheumatology\/keh297.","journal-title":"Rheumatology (Oxford)"},{"key":"9752_CR22","first-page":"2016","volume":"32","author":"GA Wells","year":"2005","unstructured":"Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landew\u00e9 RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen JS, Van der Heijde DM, van Riel PL, Wolfe F, Tugwell PS: Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol. 2005, 32: 2016-2024.","journal-title":"J Rheumatol"},{"key":"9752_CR23","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/ard.2008.090712","volume":"67","author":"LH van Tuyl","year":"2008","unstructured":"van Tuyl LH, Lems WF, Voskuyl AE, Kerstens PJ, Garnero P, Dijkmans BA, Boers M: Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis. 2008, 67: 1574-1577. 10.1136\/ard.2008.090712.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008, 372: 375-382. 10.1016\/S0140-6736(08)61000-4.","journal-title":"Lancet"},{"key":"9752_CR25","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008, 67: 1516-1523. 10.1136\/ard.2008.092932.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008, 371: 987-997. 10.1016\/S0140-6736(08)60453-5.","journal-title":"Lancet"},{"key":"9752_CR27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","volume":"64","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S: Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005, 64: 1582-1587. 10.1136\/ard.2004.034371.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR28","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","volume":"52","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005, 52: 2625-2636. 10.1002\/art.21235.","journal-title":"Arthritis Rheum"},{"key":"9752_CR29","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","volume":"64","author":"H Makinen","year":"2005","unstructured":"Makinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis. 2005, 64: 1410-1413. 10.1136\/ard.2005.037333.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/art.22619","volume":"57","author":"D Khanna","year":"2007","unstructured":"Khanna D, Oh M, Furst DE, Ranganath V, Gold RH, Sharp JT, Park GS, Keystone EC, Paulus HE: Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum. 2007, 57: 440-447. 10.1002\/art.22619.","journal-title":"Arthritis Rheum"},{"key":"9752_CR31","volume-title":"Paper presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology; 17-21","author":"R Koevoets","year":"2009","unstructured":"Koevoets R, Klarenbeek NB, van der Heijde DMFM, van Krugten MV, van Schaardenburg D, Dijkmans B, Huizinga TWJ, Kerstens P, Allaart CF: Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Paper presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology; 17-21. 2009, Abstract 957, October ; Philadelphia, PA"},{"key":"9752_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/berh.2000.0124","volume":"15","author":"WE Ollier","year":"2001","unstructured":"Ollier WE, Harrison B, Symmons D: What is the natural history of rheumatoid arthritis?. Best Pract Res Clin Rheumatol. 2001, 15: 27-48. 10.1053\/berh.2000.0124.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"9752_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.2005.044354","volume":"66","author":"B Combe","year":"2007","unstructured":"Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici H: EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007, 66: 34-45. 10.1136\/ard.2005.044354.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR34","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008, 67: 1096-1103. 10.1136\/ard.2007.080002.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR35","unstructured":"A study of tocilizumab [RoActemra\/Actemra] versus adalimumab in patients with rheumatoid arthritis. [\nhttp:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01119859\n\n]"},{"key":"9752_CR36","first-page":"CD007848","volume-title":"Cochrane Database Syst Rev","author":"JA Singh","year":"2009","unstructured":"Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez- Olivo MA, Tanjong Ghogomu E, Tugwell P: Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009, CD007848-"},{"key":"9752_CR37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.semarthrit.2009.12.002","volume":"39","author":"GJ Bergman","year":"2010","unstructured":"Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP: Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010, 39: 425-441. 10.1016\/j.semarthrit.2009.12.002.","journal-title":"Semin Arthritis Rheum"},{"key":"9752_CR38","first-page":"2398","volume":"33","author":"G Gartlehner","year":"2006","unstructured":"Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN: The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006, 33: 2398-2408.","journal-title":"J Rheumatol"},{"key":"9752_CR39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010, 69: 964-975. 10.1136\/ard.2009.126532.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR40","volume-title":"Paper presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology; 17-21","author":"R van Vollenhoven","year":"2009","unstructured":"van Vollenhoven R, Siri D, Furie R, Krasnow J, Alecock E, Alten R: Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years. Paper presented at: 73rd Annual Scientific Meeting of the American College of Rheumatology; 17-21. 2009, Abstract 1955, October ; Philadelphia, PA"},{"key":"9752_CR41","first-page":"247","volume":"31","author":"JE Fonseca","year":"2006","unstructured":"Fonseca JE, Canh\u00e3o H, Silva C, Miguel C, Mediavilla MJ, Teixeira A, Castel\u00e3o W, Nero P, Bernardes M, Bernardo A, Mariz E, Godinho F, Santos MJ, Bogas M, Oliveira M, Saavedra MJ, Barcelos A, Cruz M, Santos RA, Maur\u00edcio L, Rodrigues M, Figueiredo G, Quintal A, Patto JV, Malcata A, da Silva JC, Ara\u00fajo D, Ventura F, Branco J, Queiroz MV, Grupo de Estudos de Artrite Reumat\u00f3ide da Sociedade Portuguesa de Reumatologia: [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience]. Acta Reumatol Port. 2006, 31: 247-253.","journal-title":"Acta Reumatol Port"},{"issue":"6","key":"9752_CR42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","volume":"69","author":"J L Nam","year":"2010","unstructured":"Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewe R, Smolen JS, Emery P, Buch MH: Current evidence for the management of rheumatoid arthritis with biological diseasemodifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 69: 976-986. 10.1136\/ard.2009.126573.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"9752_CR43","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/ard.2008.091926","volume":"68","author":"A Zink","year":"2009","unstructured":"Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP: European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009, 68: 1240-1246. 10.1136\/ard.2008.091926.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3899\/jrheum.090128","volume":"82","author":"M Khraishi","year":"2009","unstructured":"Khraishi M: Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl. 2009, 82: 25-32. 10.3899\/jrheum.090128.","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"9752_CR45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","volume":"61","author":"Eugene O. Major","year":"2010","unstructured":"Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 61: 35-47. 10.1146\/annurev.med.080708.082655.","journal-title":"Annual Review of Medicine"},{"key":"9752_CR46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/rheumatology\/kel262","volume":"46","author":"T Lequerre","year":"2007","unstructured":"Lequerre T, Jouen F, Brazier M, Clayssens S, Klemmer N, Menard JF, Mejjad O, Daragon A, Tron F, Le Loet X, Vittecoq O: Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford). 2007, 46: 446-453. 10.1093\/rheumatology\/kel262.","journal-title":"Rheumatology (Oxford)"},{"key":"9752_CR47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/rheumatology\/kep112","volume":"48","author":"C Bansard","year":"2009","unstructured":"Bansard C, Lequerre T, Daveau M, Boyer O, Tron F, Salier JP, Vittecoq O, Le-Loet X: Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford). 2009, 48: 1021-1028. 10.1093\/rheumatology\/kep112.","journal-title":"Rheumatology (Oxford)"},{"key":"9752_CR48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11926-999-0014-4","volume":"1","author":"SL Bridges Jr","year":"1999","unstructured":"Bridges SL: The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response. Curr Rheumatol Rep. 1999, 1: 164-171. 10.1007\/s11926-999-0014-4.","journal-title":"Curr Rheumatol Rep"},{"key":"9752_CR49","first-page":"174","volume":"65","author":"SL Bridges Jr","year":"2007","unstructured":"Bridges SL: Personalized medicine in rheumatoid arthritis: hopes and challenges. Bull NYU Hosp Jt Dis. 2007, 65: 174-177.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"9752_CR50","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","volume":"56","author":"JA Wessels","year":"2007","unstructured":"Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TW, Guchelaar HJ: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007, 56: 1765-1775. 10.1002\/art.22640.","journal-title":"Arthritis Rheum"},{"key":"9752_CR51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/ard.2009.117622","volume":"69","author":"S Pavy","year":"2010","unstructured":"Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA, Mariette X, Coenen MJ: Tumour necrosis factor alpha -308G- > A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2010, 69: 1022-1028. 10.1136\/ard.2009.117622.","journal-title":"Ann Rheum Dis"},{"key":"9752_CR52","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS: Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007, 56: 3226-3235. 10.1002\/art.22943.","journal-title":"Arthritis Rheum"},{"key":"9752_CR53","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","volume":"48","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009, 48: 1557-1559. 10.1093\/rheumatology\/kep314.","journal-title":"Rheumatology (Oxford)"},{"key":"9752_CR54","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005, 23: S100-108.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/ar3149\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T03:03:13Z","timestamp":1581130993000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,4]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9752"],"URL":"https:\/\/doi.org\/10.1186\/ar3149","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,4]]},"article-number":"220"}}